PolyPid Ltd. (PYPD) is advancing toward key regulatory milestones with its lead therapy D-PLEX100, supported by positive Phase 3 results and preparations for a 2026 New Drug Application submission.
Alongside regulatory progress, PolyPid is strengthening its financial position, engaging in partnership discussions, and reinforcing commercial readiness, making it a notable name to follow in the biopharma space.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com